Markup Madness – Who’s Profiting from Your Prescription?Time 2022-09-24 03:26:21
MARKUP MADNESSWho’s Profiting
AtorvastatinAtorvastatin, the generic medicine for Lipitor commonly prescribed to control high cholesterol, sells to patients at retail for $46 cash. Generic drug makers sell it to their customers in the supply chain for only $1.46.
OmeprazoleOmeprazole, the prescription generic medicine for Prilosec commonly prescribed to prevent heartburn and stomach ulcers, sells to patients at retail for $74 cash. Generic drug makers sell it to their customers in the supply chain for only $0.92.
Policymakers can address these challenges and ensure the sustainability of the generic and the emerging biosimilar medicines markets. The AAM Roadmap For Ensuring Patient Access has key steps policymakers can take to ensure all Americans continue to benefit from a competitive and robust generics and biosimilars industry.
Reduce Medicare Cost Sharing for Seniors – The Ensuring Access to Lower-Cost Medicines for Seniors Act would ensure coverage of newly available generic and biosimilar medicines, reduce patient cost-sharing through proper formulary tier coverage and create a new specialty tier for biosimilars.
Eliminate the Medicaid Generics Penalty – The Protecting Access to Affordable Medicines Act would fix the misguided application of the Medicaid rebate on generic medicines, reducing the risk of drug shortages and benefiting patients through sustainable access to low-cost generics.
Address Patent Abuse – The Restoring the America Invents Act would strengthen the Inter-Partes Review process to support earlier generic entry.
Preserve the Tools that Drive Competition and Savings – Developers of generic and biosimilar medicines rely on the 180-day exclusivity period for new generics and the ability to accelerate competition through patent settlements and the “skinny label” pathway.
Resources and Media
AAM Calls on FTC to Investigate PBM Business PracticesPublic Letter
Generic Manufacturers Ask the DOJ and the FTC to Investigate Market Abuses by Buying GroupsAAM Blog
Seniors Are Still Missing Out on Savings in Medicare Part DAAM Blog
Generic Prices Are Falling, But Seniors Are Paying More for Generic Drugs. What’s Happening Here?Report
2021 U.S. Generic and Biosimilar Medicines Savings ReportReport
Sidelined: How Seniors Miss Out On Savings Available Through Generic SubstitutionReport
Access Denied: Why New Generics Are Not Reaching America’s SeniorsReport
AAM Securing Sustainable MarketsCampaign
Abuse of the patent system is keeping drug prices high for patientsAAM Blog
The Medicaid Generics Penalty: A PrimerReport
Medicare and Commercial Plans Fail to Get New Generics to PatientsPress Release
Seniors Denied Access to New, Lower-Priced Generic Drugs Due to Medicare Coverage DelaysRAPS
AAM: Medicare Part D plans slow to adopt genericsAAM Blog
The First (Price) Cut Is the Steepest
Middlemen profit-taking threatens sustained patient savings and access to generic medicines. That is #MarkupMadness! Learn more
<<< Thank you for your visit >>>